A Phase 2 interventional study of spironolactone 25 mg orally once daily and Placebo tablet to match spironolactone in Preeclampsia and Gestational Hypertension, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.
Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 35th largest by planned enrollment of the 161 interventional ones that give a count, is one of 13 that started in 2025, is one of 18 in phase 2, reaches primary completion later than 48 of the 77 other live ones, and was the 202nd registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–50 · Women only
University of California, Irvine · Sites in United States
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
Texas Southern University · Sites in United States
Ages 18–45 · Women only
Medicines360 · Sites in United States
Ages 18–99 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 24 · Phase 3 15 · Phase 4 31
First in 2000; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 204 is above the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 89 across the 161 interventional studies, 125 across the 69 observational. Of the 126 that completed or were terminated, 54 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 230 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 7 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
26 of the studies in Pre-Eclampsia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222852Phase 3Women and Infants Hospital of Rhode IslandCardiovascular Protection After Preeclampsia With Enalapril | 2027-10-15 |
| NCT07356518Wake Forest University Health SciencesTelehealth and Remote Blood Pressure | 2026-12 |
| NCT05676476University of Alabama at BirminghamThe ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy. | 2026-12 |
| NCT05924971MemorialCare Health SystemAspirin for Postpartum Patients With Preeclampsia | 2026-12 |
| NCT06523569Northwestern UniversityMobile Health Interventions to Prevent Heart Disease After Hypertensive Disorders of Pregnancy | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 230 studies in Pre-Eclampsia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.
The hypertensive disorders of pregnancy (HDP, e.g., gestational hypertension and preeclampsia) are a leading cause of maternal and infant morbidity and mortality and are associated with increased long-term risk of maternal atherosclerotic cardiovascular disease (CVD) and heart failure. The American College of Cardiology and American Heart Association now recognize the HDP as a sex-specific CVD risk factor to guide prescription of preventive statin therapy. Beyond this focused recommendation, however, targeted strategies for CVD risk reduction in women with HDP are not yet established. Maternal overweight/obesity is a risk factor for accelerated progression from HDP to chronic hypertension, a key mediator of heightened long-term CVD risk in women with a history of HDP, and for adverse cardiac remodeling in pregnancy. Recent preclinical evidence suggests that the HDP induce heightened vascular smooth muscle cell mineralocorticoid receptor (MR) sensitivity that persists postpartum, promoting chronic hypertension and CVD. In addition, the recent POP-HT trial suggested that blood pressure control in the very early postpartum period has long-lasting effects on the risk of chronic hypertension and cardiac remodeling in women after HDP. Integrating these lines of evidence, the investigators hypothesize that short-term pharmacologic blockade of the MR in the early postpartum period after HDP will yield long-term maternal cardiovascular benefits in women with overweight/obesity. To test this hypothesis, the investigators will compare a strategy of adding low-dose spironolactone, a breastfeeding-compatible MR antagonist, or placebo to usual care for 3 months following delivery with HDP. This multi-site trial will randomize 204 women with HDP and pre-pregnancy overweight/obesity delivering at Massachusetts General Hospital, Brigham and Women's Hospital, and the University of Pittsburgh-Magee Womens Hospital. The investigators will test the effect of short-term adjunctive postpartum spironolactone on 24-hour ambulatory blood pressure (Aim 1) and postpartum cardiac remodeling by echocardiography (Aim 2) at 9 months postpartum (i.e., 6 months after completion of study treatment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.
Drug: Placebo tablet to match spironolactone
Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.
Drug: spironolactone 25 mg orally once daily
Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.
Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.
Mean 24-hour ambulatory diastolic blood pressure
24-hour BP monitoring will be performed as part of end-of-study assessments using a validated ambulatory BP monitor.
Time frame: 36 weeks
Left ventricular relative wall thickness (main echocardiographic outcome)
Relative wall thickness is calculated as 2\*posterior wall thickness/LV end-diastolic diameter as measured by transthoracic echocardiography.
Time frame: Baseline and 36 weeks
Mean 24-hour ambulatory systolic blood pressure
24-hour BP monitoring will be performed as part of end-of-study assessment using a validated ambulatory BP monitor. Mean 24-hour systolic BP will be calculated from the device data.
Time frame: 36 weeks
Mean diurnal ambulatory systolic blood pressure
24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean diurnal systolic BP will be calculated from the device data.
Time frame: 36 weeks
Mean diurnal ambulatory diastolic blood pressure
24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean diurnal ambulatory diastolic blood pressure will be calculated from the device data
Time frame: 36 weeks
Mean nocturnal ambulatory systolic blood pressure
24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean nocturnal ambulatory systolic blood pressure will be calculated from the device data.
Time frame: 36 weeks
Mean nocturnal ambulatory diastolic blood pressure
24-hour BP monitoring will be performed as part of the post-treatment assessments using a validated ambulatory BP monitor. Mean nocturnal ambulatory diastolic blood pressure will be calculated from the device data.
Time frame: 36 weeks
Measured systolic blood pressure
At each visit, BP will be measured by study staff three times at one-minute intervals in accordance with multi-society guidelines for accurate measurement of blood pressure. The first measurement will be discarded, and the average of the second and third measurements will be recorded as the measured BP at each study visit.
Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks
Measured diastolic blood pressure
At each visit, BP will be measured by study staff three times at one-minute intervals in accordance with multi-society guidelines for accurate measurement of blood pressure. The first measurement will be discarded, and the average of the second and third measurements will be recorded as the measured BP at each study visit.
Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks
Readmission for hypertension
Postpartum readmission for hypertension will be captured.
Time frame: Through study completion (36 weeks post-randomization)
All-cause readmission
All postpartum readmission will be captured
Time frame: Through study completion (36 weeks post-randomization)
Daily defined doses of antihypertensive medication
Daily defined doses of antihypertensive medication will be quantified in accordance with the World Health Organization classification.
Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks
Time to discontinuation of all non-study drug antihypertensive medications
All medication changes made by treating clinicians will be captured.
Time frame: Through study completion (36 weeks post-randomization)
Escalation of antihypertensive regimen
All medication changes made by treating clinicians will be captured.
Time frame: Through study completion (36 weeks post-randomization)
Ratio of mitral E velocity to e' [E/e']
E/e', a measure of diastolic function, will be measured by transthoracic echocardiography.
Time frame: Baseline and 36 weeks
Early diastolic septal mitral annular velocity [septal e']
Septal e', a measure of diastolic function, will be measured by transthoracic echocardiography using tissue Doppler
Time frame: Baseline and 36 weeks
Peak tricuspid regurgitant jet velocity
Peak tricuspid regurgitant jet velocity, a measure of diastolic function, will be measured by transthoracic echocardiography using continuous wave Doppler
Time frame: Baseline and 36 weeks
Left atrial volume index
Left atrial volume index will be measured by transthoracic echocardiogarphy using the biplane method and indexed for body surface area.
Time frame: Baseline and 36 weeks
Ratio of E to A [E/A]
E/A, a measure of diastolic function, will be measured by transthoracic echocardiography.
Time frame: Baseline and 36 weeks
Left ventricular mass index
Left ventricular mass will be calculated from transthoracic echocardiogarphy using the Devereux formula and indexed for body surface area
Time frame: Baseline and 36 weeks
Left ventricular ejection fraction
Left ventricular ejection fraction will be measured by transthoracic echocardiogarphy using the biplane method.
Time frame: Baseline and 36 weeks
Left atrial reservoir strain
Left atrial strain, a sensitive measure of end- diastolic pressure and atrial remodeling, will be quantified using TOMTEC.
Time frame: Baseline and 36 weeks
Peak global longitudinal strain
Left ventricular global longitudinal strain, a measure of subclinical cardiac dysfunction, will be quantified using TOMTEC.
Time frame: Baseline and 36 weeks
Interventricular septal wall thickness
Interventricular septal wall thickness will be measured by transthoracic echocardiography from the parasternal long axis view.
Time frame: Baseline and 36 weeks
Posterior wall thickness
Posterior wall thickness will be measured by transthoracic echocardiography from the parasternal long axis view.
Time frame: Baseline and 36 weeks
High-sensitivity cardiac troponin I
High-sensitivity cardiac troponin will be measured using standard clinical assays.
Time frame: Baseline, 12 weeks, and 36 weeks
N-terminal pro-B-type natriuretic peptide
NT-proBNP will be measured using standard clinical assays.
Time frame: Baseline, 12 weeks, and 36 weeks
Urine microalbumin/creatinine
Urine microalbumin/creatinine will be measured using standard clinical assays.
Time frame: 2 weeks, 12 weeks, and 36 weeks
Activin A
Activin A will be measured by ELISA.
Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks
Soluble fms-like tyrosine kinase receptor-1
sFlt-1 will be measured by ELISA.
Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks
Placental growth factor
Placental growth factor will be measured by ELISA.
Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks
Procollagen type I carboxyterminal propeptide
PICP will be measured by enzyme immunoassay.
Time frame: Baseline, 12 weeks, and 36 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Spironolactone
Massachusetts General Hospital →